Information Provided By:
Fly News Breaks for December 9, 2016
LLY, BIIB
Dec 9, 2016 | 08:21 EDT
RBC Capital analyst Michael Yee says that Eli Lilly's (LLY) Alzheimer's drug, Solanezumab, performed better than expected in a clinical trial. After investors thought that the drug was "a total disappointment" following Lilly's announcement that it had missed its primary endpoint, additional data showed that the treatment improved "several clinical cognitive and functional endpoints " by 7%-15% versus placebo, while the primary endpoint improvement was statistically significant during weeks 28-64, although not at the end of the 80 week trial, Yee reported. Based on the data, the analyst thinks that "a better...more potent drug" like Biogen's (BIIB) Alzheimer's treatment, aducanumab "is more likely to work." He keeps an Outperform rating on Biogen.
News For BIIB;LLY From the Last 2 Days
LLY
Mar 18, 2024 | 10:41 EDT
Oprah Winfrey is hosting a television special on Monday to discuss how WeightWatchers (WW) and weight loss drugs helped her with weight and obesity, CNN's Lisa Respers France reports. "An Oprah Special: Shame, Blame and the Weight Loss Revolution" will be a sit-down conversation around the "radical impact of prescription weight loss medications," according to promotional material for the special. Winfrey, who recently exited the board of WW, will moderate the conversation in front of a live audience with medical experts to explore "prevailing questions and concerns surrounding the impact on our health care, economy, lifestyle and culture," according to a press release for the event. "It is a very personal topic for me and for the hundreds of millions of people impacted around the globe who have for years struggled with weight and obesity," Winfrey said. Weight loss drug options include Eli Lilly's (LLY) Mounjaro and Novo Nordisk's (NVO) Ozempic. Reference Link